Daniel Blessing

Daniel Blessing is a seasoned biotechnology professional, currently serving as Co-Founder, Chief Technology Officer, and Board Director at HAYA Therapeutics since May 2019. Prior to this role, Daniel held the position of InnoTREK fellow at CHUV | Lausanne University Hospital, focusing on therapeutic strategies related to heart-specific long non-coding RNAs. A PhD student at the University of Lausanne from April 2014 to May 2018, Daniel specialized in the development and optimization of recombinant Adeno-associated virus (rAAV) vectors for gene therapy. Daniel's academic background includes a Master's degree in Applied and Molecular Biotechnology from RWTH Aachen University and a Bachelor's degree in Bio and Process Engineering from Hochschule Furtwangen. Previous research experience includes positions at the Fraunhofer Institute for Molecular Biology and Applied Ecology and the Max Planck Institute for Marine Microbiology, highlighting a strong foundation in biopharmaceutical production and microbiology.